EXCERPT:
February 11, 2019 – Invitrocue Limited (ASX: IVQ), a leading healthcare bio-analytic solutions provider, is pleased to announce the establishment of InvivoCue, a joint venture (JV) between Invitrocue and A*STAR scientist Dr. Chen Qingfeng. Invitrocue will own 70% of the Company, while Dr Chen will own 30%. The JV will supply humanised immune system mice and cell products to research institutions, pharmaceutical, clinical research and biotechnology companies.
InvivoCue will offer mice with a stable and functional Human Immune system (HiMice) as well as immunodeficient mice (NIKO) and its related organ-specific immune cells for both in vivo and in vitro studies. Additional services will include immune-related toxicity and drug efficacy assessments for immunotherapeutic drug development.
Please click below to read full announcement.
Click to download PDF.
